Non-Current Assets
Indefinite-Lived Research and Development Assets
Abbott Indefinite-Lived Research and Development Assets increased by 33.0% to $1.20B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 53.1%, from $784.00M to $1.20B. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionNon-Current Assets
CategoryGrowth
SignalHigher is better
VolatilityModerate
First reportedQ4 2021
Last reportedQ1 2026Apr 29, 2026
How to read this metric
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
Detailed definition
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Peer comparison
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
Metric ID:
indefinite_lived_rd_assetsHistorical Data
17 periods
| Q4 '21 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $0.00 | $919.00M | $807.00M | $319.00M | $807.00M | $822.00M | $832.00M | $568.00M | $787.00M | $798.00M | $798.00M | $773.00M | $784.00M | $789.00M | $894.00M | $902.00M | $1.20B |
| QoQ Change | — | — | -12.2% | -60.5% | +153.0% | +1.9% | +1.2% | -31.7% | +38.6% | +1.4% | +0.0% | -3.1% | +1.4% | +0.6% | +13.3% | +0.9% | +33.0% |
| YoY Change | — | — | — | — | — | -10.6% | +3.1% | +78.1% | -2.5% | -2.9% | -4.1% | +36.1% | -0.4% | -1.1% | +12.0% | +16.7% | +53.1% |
Range$0.00 – $1.20B
Avg YoY Growth+14.8%
Median YoY Growth+1.4%
Current Streak5 quarters growth
Indefinite-Lived Research and Development Assets at Other Companies
Frequently Asked Questions
- What is Abbott's indefinite-lived research and development assets?
- Abbott (ABT) reported indefinite-lived research and development assets of $1.20B in Q1 2026.
- How has Abbott's indefinite-lived research and development assets changed year-over-year?
- Abbott's indefinite-lived research and development assets increased by 53.1% year-over-year, from $784.00M to $1.20B.
- What does indefinite-lived research and development assets mean?
- The value of ongoing research projects acquired from other companies that are not yet ready for sale.